Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL)

被引:22
|
作者
Braess, J
Reich, K
Willert, S
Strutz, F
Neumann, C
Hiddemann, W
Wörmann, B
机构
[1] Univ Gottingen, Klinikum Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany
[2] Klinikum Gottingen, Dept Nephrol, Gottingen, Germany
[3] Klinikum Gottingen, Dept Dermatol, Gottingen, Germany
关键词
fludarabine; autoimmune side effects; lymphoma; T cell; pemphigus;
D O I
10.1007/s002770050347
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 40-year-old patient with low-grade B-NHL developed a generalized macular-papular rash following the first cycle of fludarabine treatment which progressed to a complete epidermal necrolysis following the second cycle. Clinical symptoms and the results of the direct and indirect immunofluorescence were consistent with a mucocutaneous autoimmune syndrome (pemphigus). Immunohistochemical analysis demonstrated a dense epidermal infiltration of CD8+ lymphocytes associated with the histological features of single-cell necrosis of keratinocytes. Early and aggressive immunosuppressive treatment with steroids, cyclophosphamide, and high-dose immunoglobulins resulted in regression of symptoms and complete reconstitution of epidermal integrity. The malignant lymphoma has completely regressed. The findings suggest a fludarabine-induced defect in immunosurveillance - resulting in the uncontrolled activation of autoaggressive T-cell clones - as a pathogenetic mechanism of this life-threatening dermatological complication.
引用
收藏
页码:227 / 230
页数:4
相关论文
共 50 条
  • [1] Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL)
    J. Braess
    K. Reich
    S. Willert
    F. Strutz
    C. Neumann
    W. Hiddemann
    B. Wörmann
    Annals of Hematology, 1997, 75 : 227 - 230
  • [2] Hypocomplementemic urticaria with underlying low-grade non-Hodgkin's B-cell lymphoma
    Aldridge, C
    Choudhury, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P140 - P140
  • [3] Phase II study of oral Fludarabine (FAMP) in combination with rituximab in indolent B-cell non-hodgkin lymphoma (B-NHL)
    Ishizawa, Kenichi
    Tobinai, Kensei
    Ogura, Michinori
    Itoh, Kuniaki
    Aorishima, Yasuo
    Ando, Kiyoshi
    Yamamoto, Joji
    Watanabe, Takashi
    Uchida, Toshiki
    Nakata, Masanobu
    Hayashi, Masaki
    Hotta, Tomomitsu
    BLOOD, 2007, 110 (11) : 387A - 387A
  • [4] Overt B-cell non-Hodgkin's lymphoma (B-NHL): Role of hepatitis C virus (HCV).
    Germanidis, G
    Haioun, C
    Gaulard, P
    Reyes, F
    Dhumeaux, D
    Pawlotsky, JM
    HEPATOLOGY, 1999, 30 (04) : 605A - 605A
  • [5] Overt B-cell non-Hodgkin's lymphoma (B-NHL):: Role of hepatitis C virus (HCV)
    Germanidis, G
    Haioun, C
    Gaulard, P
    Castéra, L
    Reyes, F
    Dhumeaux, D
    Pawlotsky, JM
    JOURNAL OF HEPATOLOGY, 2000, 32 : 99 - 99
  • [6] Low-grade non-Hodgkin B-cell lymphoma presenting as sensory neuropathy
    Gemignani, F
    Marchesi, G
    DiGiovanni, G
    Salih, S
    Quaini, F
    NobileOrazio, E
    EUROPEAN NEUROLOGY, 1996, 36 (03) : 138 - 141
  • [7] Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma
    Misgeld, E
    Germing, U
    Aul, C
    Gattermann, N
    LEUKEMIA RESEARCH, 2001, 25 (01) : 95 - 98
  • [8] Multicenter phase II study of oral fludarabine phosphate (FAMP) in relapsed indolent B-cell non-Hodgkin lymphoma (B-NHL)
    Morishima, Y
    Ogura, M
    Tobinai, K
    Minami, H
    Hayashi, M
    Hotta, T
    ANNALS OF ONCOLOGY, 2005, 16 : 155 - 155
  • [9] Where is the place for rituximab in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) of children and adolescents?
    Patte, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 110 - 110
  • [10] Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B-cell non-Hodgkin lymphoma (B-NHL).
    Solh, Melhem
    Alderuccio, Juan Pablo
    Stathis, Anastasios
    Ungar, David
    Liao, Sam
    Khouri, Lisa
    Zhang, Xiaoyan
    Boni, Joseph
    CANCER RESEARCH, 2021, 81 (13)